Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
ASX:PIQ'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.64 Med: 14 Max: 46.5
Current: 6.5
During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of Proteomics International Laboratories was 46.50. The lowest was 4.64. And the median was 14.00.
ASX:PIQ's Price-to-Net-Current-Asset-Value is ranked worse than 59.24% of 942
companies
in the Biotechnology industry
Industry Median: 4.89
vs ASX:PIQ: 6.50
Proteomics International Laboratories (ASX:PIQ) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Proteomics International Laboratories Net Current Asset Value Related Terms
Proteomics International Laboratories Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories Net Current Asset Value Chart
ASX:PIQ vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Proteomics International Laboratories's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.03 mean?
Proteomics International Laboratories (ASX:PIQ) has a Net Current Asset Value of A$0.03 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Proteomics International Laboratories and its competitors. This is 100% below median its historical median of 14.00. Over the past decade, Proteomics International Laboratories' Net Current Asset Value has ranged from 4.64 to 46.50. According to the industry distribution chart, Proteomics International Laboratories ranks #558 out of 942 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Proteomics International Laboratories' Net Current Asset Value too high?
Proteomics International Laboratories' current Net Current Asset Value of A$0.03 is 100% below median its 10-year median of 14.00. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 46.50. Based on the distribution chart, Proteomics International Laboratories ranks #558 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Proteomics International Laboratories has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #558 out of 942 companies for Net Current Asset Value. This places Proteomics International Laboratories in the lower half of its industry. The industry median Net Current Asset Value is 4.89. Historically, Proteomics International Laboratories' own Net Current Asset Value has ranged from 4.64 to 46.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.89, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Net Current Asset Value is A$0.03, which is 100% below median its own 10-year median of 14.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (ASX:PIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.48, compared to a current price of A$0.20 — trading 59.4% below its estimated fair value. The current Net Current Asset Value is A$0.03, which is 100% below median its 10-year median of 14.00. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Proteomics International Laboratories (ASX:PIQ), the current Net Current Asset Value is A$0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (ASX:PIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of A$0.20 is trading 59.4% below its estimated GF Value™ of A$0.48.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for ASX:PIQ:
Net Current Asset Value: A$0.03 (100% below median its 10-year median of 14.00)
GF Value™: A$0.48 vs. price of A$0.20 (59.4% below fair value)
No single metric tells the full story. See the ASX:PIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for ASX:PIQ
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PIQ has been successfully added to your 
